(Memphis, TN/March 18, 2009) Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, recently launched a Drug, Device & Life Sciences Industry Service Team, combining resources from its nationally recognized health law, business, intellectual property, and product liability practices to address the increasing multidisciplinary needs of pharmaceutical, medical device, and life sciences clients. With more than 80 members firm-wide, the Drug, Device & Life Sciences team is one of the country’s largest such groups and is uniquely positioned to provide a comprehensive range of capabilities. The group’s attorneys provide counsel in the changing legislative, regulatory and economic environment and advise on strategies for successful interaction with the Food & Drug Administration, mergers and acquisitions, intellectual property, customs, labor and employment, government investigations, product liability issues and litigation matters.
“Changes such as recent and pending court decisions, evolving litigation climates, and of course, the economy, present significant challenges to our clients that we are well prepared to address. We created this group to help medical device companies, medical equipment and supply companies, pharmaceutical companies and bioscience companies confront these problems comprehensively,” said J. Carter Thompson, Jr., co-chair of the Drug, Device & Life Sciences team.
Mr. Thompson, who also leads the Firm’s Product Liability & Mass Tort Practice Group, concentrates his practice in the national, regional and local defense of drug and medical device and other product liability cases.
“A balanced complement to our nationally top ranked health law and product liability practices, this team harnesses our strengths from across the firm, delivering an integrated approach using multidisciplinary teams. While we have already been providing these capabilities to our clients, having a formalized Drug, Device & Life Sciences team allows us to provide a robust program that tremendously enhances our client service firm-wide,” said Richard G. Cowart, head of the Firm's Health Law Department.